Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hey Scored, looks quite interesting, I have looked before - I remember the building picture on their website. Looks like you timed your purchase well.
I will look into this one further, although I am currently avoiding any more biotech / pharma.
I am also looking at GILD (e-sports).
Thanks for the suggestion, always good to hear new ideas.
ALB
Hi HunSeN I just bought a tiny amount 4800 shares we see where rua goes something is telling me buy this way if it goes sour it’s not to bad atb pd 138.75 where as early on was offered 136.3 that’s life
Hi HunSeN the company is rua life sciences only 22 million shares 30 million mkt capt looks interesting I did not buy as after studying I feel it be six months before big move What with dnl slow I don’t want to. Have the same type of share . It might suit you or another I really like is vel- velocity composites mkt capt 8 million 36 million shares atb I got carried away but I can wait as they need to submit a 501 k form . However rua I feel could be good in time
Hey Scored, sounds interesting, will look out for your post. Thanks.
Think I found a new gem it looks exciting low mkt capt which I like great products more to come soon . Will update Monday or tue looks like it will rerate sharp soon
I’ve never seen a share with so much going for it be this stagnant
And no intrest 63 p to sell so I bought all the way down and don’t get me wrong I’m sweet here . I’m happy how I use dnl . But it don’t makes sense what we been approved for and others haven’t got fda etc and 300 million plus mkt capt ! Would love to add another lot but how far will it drift ? I’m just so glad I did not pay 70 p like a few in offer . Dnl don’t hold it gains . Yes long term great but if I didn’t work dnl like I do I be fed up . Hi HunSeN albino has answered what I would of said . Hope your well glad the weekend is here soon to get away from this .
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=441614
On this link the exclusivity section is blank so perhaps that is pending but perhaps a formality now approved?
The info from the time suggests orphan status was in play - wonder if the wording is confusing "following Orphan Status approval" i.e. now that it is in place, a $2.5 payment will be due on first sales - or is there a separate process post FDA approval?
https://www.globenewswire.com/news-release/2020/03/27/2007542/0/en/Eton-Pharmaceuticals-Announces-Acquisition-of-U-S-Marketing-Rights-to-Pediatric-Orphan-Drug-Alkindi-Sprinkle.html
"The FDA has granted Alkindi Sprinkle Orphan Drug Designation and as a result, the product is expected to receive seven years of Orphan Drug Exclusivity after approval. In addition, Diurnal has been issued three formulation and method of use patents in the United States which extend out as far as 2034. All three patents are expected to be Orange Book listed after the product’s approval. The safety and efficacy of the product is supported by six clinical, bioequivalence, and safety studies conducted by Diurnal prior to the submission of the product’s NDA."
Morning Scored,
your point on Eton milestone payment is interesting, here is a snip from the agreement
"Under the terms of the licence agreement, Diurnal will receive a non-refundable upfront payment of $5.0 million, of which $3.5 million is in cash and $1.5 million is through the issue to Diurnal of 379,474 new Eton shares, and will receive an additional $2.5 million cash milestone payment upon first commercial sale in the US following regulatory approval and grant of Orphan Drug Status (currently anticipated in Q4 2020). "
So, the first milestone payment $5m was made, US regulatory approval is done and Eton have made sales, BUT, I'm not sure that they have Orphan status - which is the last condition to receive the next $2.5m milestone payment.
I'm not sure what's happening with Alkindi Orphan status?
Any ideas?
adx at 17 now over 20 should be a rebound -- picked up 20k at 65,02 -if she drifts will add i feel between 62/64 lows
One good thing about slow days is when a few buys come in you know news is looming.
TO see how eton sales figures will be soon and if we are any nearer to our pay out by them . AT least the chinesse have paid us . ATM i never seen dnl so slow for trades lets hope it picks up soon
As a heavily II backed £100m mcap company I think it should hold well but may mean upward moves are also pretty steady.
The SP has actually grown very strongly over the last year or so, I think it just lacks a bit of near term sparkle to crack on - not sure a paid for presentation via sharesoc helps get lots of PIs onboard though.
I am happy to keep building a position anywhere under a quid without bad news, many got in following the Eton deal last year for the Alkindi FDA approval and then hung on for Efmody Euro news, for some maybe hard to see the next big near term catalyst (not entirely sure myself). P3 for USA Efmody to restart later this year, 2023 likely best commercial hope if all goes to plan, so really we are looking for commercial traction with Alkindi, indications of initial early sales interest for Efmody in Europe (maybe later this year) , would be good to see some news on Ditest as the potential there may draw some wider interest - Japan and UK news/deals maybe not far away, milestone payment confirmations - Then I guess it is other tie ups around the world that may become apparent.
Anyone got a view on the nearest big news they hope for?
Scored DNL is a Solid share. Please see the 1 year chart of where it’s heading. People that are selling have either been in since early days with 20p buy in price etc, or are impatient. As we know.... once the herd arrives it can go up 50-100% in one day. Let’s look at the bigger picture here, sit tight and wait for the bigger gains.
SAR raises money at 2.8p now 4,5p in days why is dnl so unloved ?
We must have a seller as can buy well over 100000 at 67 p no problems . Unless market marker is shorting it down .Games they play
25K at 67 as big buys are coming in . Kept poeder if she drops .ANY way im sure 3 rd quarter we will rerate .I WILL be happy with 75p then
Nice order in at 66p . Really cant make dnl out when you compare other companys -- WE GOT IT ALL really lets hope we are over a pound by jan 22
Picked up a few at 68 more powder ready as feel she will drift down . ITS slow here however a new partner could set us alight he he
On those sort of figures I will be retiring in 9 years time with my current investment
Eh ??
£1.53 eps by 2030 !!
Wowser .
Great research note see by 2030 profits of nearly 500 million whew -- SURELY this would be 10 pound a share ? See how calvin has upped the target from a pound approx .. IMO looking good slight drift will buy more .THIS is a keeper and if those figures happen i can see a nice buy out but just our luck it happen before dnl gets going ,Research note dont rule out another fund raise ,THOUGHT we was sound but feel we are good for another year .Goodluck all
Assuming they are using Calvine over Hardman as not seen any recent "notes" from them.
Very detailed round up though, covering likely steps ahead, opportunities and risks, as well as helping unpack the potential upside significance of recent newsflow.
I had probably not realised the lengthy timescale to reinstate phase 3 for the USA (through to potential FDA approval maybe 2023), but chances of success sound promising, especially if SPA confirmed. Also interesting why the US market is so important (not just because it is a big country/market).
However if they are successful in maximising Efmody sales into all potential markets/treatment scenarios there really is quite substantial revenue on offer (AI a key area).
https://www.calvinepartners.com/diurnal-group-efmody-eu-approval
Another good write up